CA2144936A1 - Antibody conjugates with improved properties - Google Patents

Antibody conjugates with improved properties

Info

Publication number
CA2144936A1
CA2144936A1 CA002144936A CA2144936A CA2144936A1 CA 2144936 A1 CA2144936 A1 CA 2144936A1 CA 002144936 A CA002144936 A CA 002144936A CA 2144936 A CA2144936 A CA 2144936A CA 2144936 A1 CA2144936 A1 CA 2144936A1
Authority
CA
Canada
Prior art keywords
antibody
conjugate
carrier protein
conjugate according
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002144936A
Other languages
English (en)
French (fr)
Inventor
Brendan Murray
Terence O'reilly
Gerd Pluschke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Ciba Geigy AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy AG filed Critical Ciba Geigy AG
Publication of CA2144936A1 publication Critical patent/CA2144936A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CA002144936A 1994-03-21 1995-03-17 Antibody conjugates with improved properties Abandoned CA2144936A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP94810173.8 1994-03-21
EP94810173 1994-03-21

Publications (1)

Publication Number Publication Date
CA2144936A1 true CA2144936A1 (en) 1995-09-22

Family

ID=8218230

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002144936A Abandoned CA2144936A1 (en) 1994-03-21 1995-03-17 Antibody conjugates with improved properties

Country Status (11)

Country Link
JP (1) JPH0820545A (fi)
KR (1) KR950031111A (fi)
AU (1) AU1481795A (fi)
CA (1) CA2144936A1 (fi)
FI (1) FI951276A (fi)
HU (1) HUT71776A (fi)
IL (1) IL113022A (fi)
NO (1) NO951061L (fi)
NZ (1) NZ270734A (fi)
RU (1) RU95104325A (fi)
ZA (1) ZA952269B (fi)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2865737B1 (fr) * 2004-02-03 2006-03-31 Anteis Sa Gel reticule biocompatible

Also Published As

Publication number Publication date
IL113022A0 (en) 1995-06-29
AU1481795A (en) 1995-09-28
FI951276A (fi) 1995-09-22
ZA952269B (en) 1995-09-21
HU9500586D0 (en) 1995-04-28
FI951276A0 (fi) 1995-03-17
JPH0820545A (ja) 1996-01-23
HUT71776A (en) 1996-01-29
KR950031111A (ko) 1995-12-18
IL113022A (en) 2000-02-29
NZ270734A (en) 1997-05-26
RU95104325A (ru) 1996-12-27
NO951061D0 (no) 1995-03-20
NO951061L (no) 1995-09-22

Similar Documents

Publication Publication Date Title
US4400376A (en) Immunological preparations
US5019387A (en) Production of antibodies to HIV
US5013548A (en) Production of antibodies to HIV
AU668870B2 (en) Targeted delivery of genes encoding immunogenic proteins
US4950480A (en) Enhancement of antigen immunogenicity
CN100586481C (zh) 用于治疗或预防尼古丁成瘾的半抗原-载体偶联物
KR100498198B1 (ko) 알레르기에 대한 백신접종 및 치료를 위한 펩티드 임뮤노겐
RU2120805C1 (ru) Вакцина, обладающая способностью вызывать иммунный ответ против собственного jge организма, способ получения вакцины и способ иммунизации млекопитающего против опосредуемых jge аллергических реакций
EP0467714A1 (en) The class II protein of the outer membrane of neisseria meningitidis
CN101557821A (zh) 作为疟疾疫苗的恶性疟原虫表面蛋白的偶联物
RU2253655C2 (ru) Антиидиотипическое антитело к антителам, ингибирующим связывание иммуноглобулина с его высокоаффинным рецептором
US5601826A (en) Peptide which produces protective immunity against tetanus
AU624324B2 (en) Conjugate malaria vaccine
EP0597838B1 (en) Vaccine compositions
US20040030106A1 (en) Novel compounds and process
EP0166548A2 (en) Broad spectrum vaccine against gonorrhea
CA2144936A1 (en) Antibody conjugates with improved properties
KR20020007313A (ko) IgE의 C-엡실론-2 도메인으로부터 유도된 에피토프또는 미모토프, 이들의 길항제 및 이들의 치료학적 용도
AU3798699A (en) Antibody conjugates with improved properties
EP0674907A2 (en) Conjugabes of a antibody and a carrier protein, useful for active immunotherapy
CA2262427A1 (en) Conjugated peptides, immunological reagent containing same and use thereof for treatment of immunological disorders
US4622223A (en) Broad spectrum vaccine against gonorrhea
NZ286599A (en) use of protein antibody conjugate for stimulating an immune response
US5173293A (en) Anti-T-cell antibodies as adjuvants
WO1994000487A1 (en) Peptide which produces protective immunity against tetanus

Legal Events

Date Code Title Description
FZDE Discontinued